iBio Appoints Endocrinologist Molly Carr as Chief Medical Officer, Grants 430K Inducement Options
IBIO has more than doubled off its 52-week low of $0.556.
Summary
iBio appointed Dr. Molly Carr, formerly of Eli Lilly, as Chief Medical Officer to lead clinical strategy for its obesity and cardiometabolic pipeline. The hire comes with a $470K salary and 430,000 inducement stock options.
Key Events · Executive and Board Changes · IBIO
-
CMO Appointment
Dr. Molly Carr, M.D., appointed Chief Medical Officer effective July 31, 2026. She previously served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly, overseeing late-stage development of efsitora and other metabolic disease programs.
-
Compensation Package
Annual base salary of $470,000, target bonus of 40% of base salary, and standard benefits. Severance includes 9 months' salary and COBRA upon termination without cause, with enhanced benefits upon a change in control.
-
Inducement Option Grant
Granted 430,000 non-qualified stock options with an exercise price of $1.40 (closing price on grant date), 10-year term, vesting 25% after one year and the remainder monthly over 36 months. The grant was made outside the equity plan as an inducement under Nasdaq Rule 5635(c)(4).
-
Strategic Context
The hire strengthens clinical leadership as iBio advances IBIO-600 (Phase 1) and IBIO-610 (preclinical obesity candidate) toward later-stage development. Dr. Carr's endocrinology expertise aligns with the company's cardiometabolic focus.
Analysis · IBIO · Life Sciences
iBio hired Dr. Molly Carr, a veteran endocrinologist from Eli Lilly, as Chief Medical Officer — a strategic move as the company advances its obesity and cardiometabolic pipeline into later-stage trials. Her compensation includes a $470K salary, 40% target bonus, and an inducement option grant for 430,000 shares at $1.40, the July 31 closing price. The appointment fills a critical clinical leadership gap and signals iBio's transition to a clinical-stage organization, but the option grant represents modest dilution (less than 1% of outstanding shares) and is standard for a C-suite hire.
At the time of this filing, IBIO was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.5M. The 52-week trading range was $0.56 to $3.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.